FDC Q2 FY27 Revenue Jumps 21% to ₹572 Crore, PAT Soars 73%
FDC Limited reported Q2 FY27 revenue of ₹572 crore, up 21% Y-o-Y. PAT surged 73% to ₹49 crore. Domestic Formulations grew 22.6% and International Formulations 28.5%. EBITDA margin improved to 11.2%. The company was the fastest-growing among the top 25 in the Indian Pharmaceutical Market in Q2 FY27.
The results show a significant turnaround and strong growth across key financial metrics and business segments, which is likely to positively impact investor sentiment and the company's stock performance.
The company reported strong year-on-year growth in revenue, profit after tax, and EBITDA, with significant improvements in EBITDA margin and key business segments showing robust performance.
FDC Limited announced its unaudited consolidated financial results for the second quarter and half-year ended September 30, 2026. The company reported a revenue from operations of ₹572 crore for Q2 FY27, marking a significant year-on-year increase of 21.0% compared to ₹473 crore in Q2 FY26. For the half-year ended September 30, 2026 (H1 FY27), revenue from operations stood at ₹1,240 crore, a 10.6% increase from ₹1,121 crore in H1 FY26.
EBITDA for Q2 FY27 was reported at ₹64 crore, a substantial increase of 90.2% from ₹34 crore in Q2 FY26, with the EBITDA margin improving to 11.2% from 7.1%. For H1 FY27, EBITDA reached ₹210 crore (margin 16.9%), up from ₹176 crore (15.7%) in H1 FY26.
Profit before tax (PBT) for Q2 FY27 was ₹65 crore, a 71.7% increase from ₹38 crore in Q2 FY26. Profit after tax (PAT) for the quarter stood at ₹49 crore, up 72.9% from ₹28 crore in the corresponding period last year. Earnings per share (EPS) for the quarter was ₹3.01, compared to ₹1.75 in Q2 FY26. For H1 FY27, PAT increased by 21.3% to ₹181 crore from ₹150 crore in H1 FY26, with EPS at ₹11.15.
Segment-wise performance highlights include Domestic Formulations returning to growth with revenue of ₹467 crore in Q2 FY27, up 22.6% year-on-year, driven by brands like Electral and Enerzal. International Formulations sustained momentum, growing 28.5% year-on-year in Q2 FY27 to ₹75 crore, and showing robust growth of 47.6% for H1 FY27 to ₹148 crore. The API business recorded sales of ₹28 crore in Q2 FY27, a slight decrease of 4.8% year-on-year.
What to do with a filing like this
FDC Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by FDC Limited. Read the original for the full detail.